Lopinavir + RitonavirThird Party Manufacturing in India

Lopinavir + Ritonavir is a fixed-dose combination of two HIV protease inhibitors used in the management of HIV-1 infection. Lopinavir provides the primary antiviral activity by binding to the active site of HIV-1 protease, an enzyme essential for the cleavage of viral Gag-Pol polyprotein precursors. By inhibiting this enzyme, lopinavir prevents the formation of mature, infectious viral particles, thereby blocking viral replication. Ritonavir serves as a pharmacokinetic booster — it is a potent inhibitor of the CYP3A4 isoenzyme in the liver and intestine, which is the primary metabolic pathway for lopinavir. By suppressing CYP3A4-mediated metabolism, ritonavir significantly increases lopinavir plasma concentrations, allowing for lower dosing and extended duration of antiviral effect. The combination is well-established as a cornerstone of highly active antiretroviral therapy (HAART) and is used alongside other antiretroviral agents to achieve viral suppression and immune reconstitution in HIV-positive patients.

Therapeutic Uses

Lopinavir + Ritonavir is prescribed as part of combination antiretroviral therapy for the treatment of HIV-1 infection:

• HIV-1 Infection: Used in adults and pediatric patients (14 days and older) to achieve viral suppression, reduce HIV RNA levels, and increase CD4 cell counts.
• Post-Exposure Prophylaxis (PEP): Recommended as an alternative regimen for occupational and non-occupational HIV exposure prevention in conjunction with other antiretrovirals.
• Prevention of Mother-to-Child Transmission: Used in特定的 pregnancy protocols to reduce the risk of vertical HIV transmission.

Why Manufacturers Choose Lopinavir + Ritonavir

Lopinavir + Ritonavir remains a widely prescribed protease inhibitor combination in national HIV treatment programs across India, Africa, and Southeast Asia. Its proven efficacy, established safety profile, and inclusion in WHO Essential Medicines List ensure consistent demand from government procurement agencies and global health organizations. The fixed-dose combination simplifies dosing and improves adherence compared to separate administration of each component. Indian manufacturers with WHO-GMP certified facilities are well-positioned to supply this critical antiretroviral to domestic and export markets, particularly to PEPFAR-supported and Global Fund programs.

This makes Lopinavir + Ritonavir one of the most important antiretroviral combinations for third party manufacturing in India, with consistent institutional and government buyer demand.